Skip to main content
Log in

Pharmacodynamics of the antiarrhythmic disopyramide in healthy humans: Correlation of the kinetics of the drug and its effects

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The effects on heart rate, R-T' interval, and mean arterial blood pressure were studied in seven healthy male volunteers after intravenous (1 and 2 mg/kg) and oral (3 and 6 mg/kg) administration of the quinidine-like antiarrhythmic disopyramide phosphate, 4-diisopropylamino-2-phenyl-2-(2-pyridyl)butyramide phosphate. The left ventricular ejection time was measured after intravenous administration of 2 mg/kg of drug. Simultaneously the plasma concentrations and urinary excretion of the parent drug and its main metabolite, the monodealkylated product, were monitored as a function of time. Heart rate increases of 20% were observed at 2 mg/kg i.v. and 6 mg/kg p.o. and peaked at 0–4 min and 2 hr after administration, respectively. R-T' interval increases of 40% and 9% were observed at 2 mg/kg and 1 mg/kg i.v., respectively, and peaked at 0–2 min after administration. R-T' interval increases of 12% and 4% were observed at 6 mg/kg and 3 mg/kg p.o., respectively, and peaked at 2.5 hr. The ejection time index was unchanged, and although a 5–10% increase in the mean arterial blood pressure was observed in the 11 hr after administration, there was no pattern consistent with size or mode of administration of the four different dosages.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. B. Befeler, A. Castellanos, Jr., D. E. Wells, M. C. Vagueiro, B. K. Yeh, and R. J. Myerburg. Electrophysiological effects of disopyramide phosphate: A new antiarrhythmic agent.Am. J. Cardiol. 35:282–287 (1975).

    Article  CAS  PubMed  Google Scholar 

  2. J. F. Conway, K. Bottomley, E. J. Wakeley, and R. S. Dugg. Disopyramide in cardiac arrhythmias—An initial appraisal.J. Int. Med. Res. 1:107–114 (1973).

    Google Scholar 

  3. J. Desruelles and A. Gerard. Indications et resultats due disopyramide dans les troubles due rythme cardiaque.Mouvement Ther. 2:95–108 (1970).

    Google Scholar 

  4. J. Granier. Un nouvel antiarythmique: Le disopyramide.Presse Med. 76:1605–1606 (1968).

    CAS  PubMed  Google Scholar 

  5. G. Härtel, A. Louhija, and A. Konttinen. Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion.Clin. Pharmacol. Ther. 15:551–555 (1974).

    PubMed  Google Scholar 

  6. M. J. Katz, C. E. Meyer, A. El-Etr, and S. J. Slodki. Clinical evaluation of a new antiarrhythmic agent, SC-7031.Curr. Ther. Res. 5:343–350 (1963).

    CAS  PubMed  Google Scholar 

  7. L. A. Vismara, D. T. Mason, and E. A. Amsterdam. Disopyramide phosphate: Clinical efficacy of a new oral antiarrhythmic drug.Clin. Pharmacol. Ther. 16: 330–335 (1974).

    CAS  PubMed  Google Scholar 

  8. R. S. Dreifus, Z. Filip, D. M. Sexton, and Y. Watanabe. Electrophysiological and clinical effects of a new antiarrhythmic agent: Disopyramide.Am. J. Cardiol. 31: 129 (1973).

    Google Scholar 

  9. P. P. Mathur. Cardiovascular effects of a newer antiarrhythmic agent, SC-7031.Curr. Ther. Res. 5:343–350 (1963).

    Google Scholar 

  10. B. K. Yeh, P. K. Sung, and B. J. Scherlag. Effects of disopyramide on electrophysiological and mechanical properties of the heart.J. Pharm. Sci. 62:1924–1929 (1973).

    Article  CAS  PubMed  Google Scholar 

  11. A. Sekyia and E. M. Vaughan Williams. A comparison of the antifibrillatory actions and effects on intracellular cardiac potentials of pronethalol, disopyramide and quinidine.Br. J. Pharmacol. Chemother. 21:473–481 (1963).

    Article  Google Scholar 

  12. R. R. Dean and D. M. Ferguson. Effects of disopyramide on the a-v conduction system.Arch. Int. Pharmacodyn. 190:183–189 (1971).

    CAS  PubMed  Google Scholar 

  13. C. M. Mokler and C. G. Van Arnam. Pharmacology of a new antiarrhythmic agentγ-diisopropylamino-α-phenyl-α-(2-pyridyl)-butyramide (SC-7031).J. Pharmacol. Exp. Ther. 136:114–124 (1962).

    CAS  PubMed  Google Scholar 

  14. C. M. Mokler and R. A. Hillman. Nature of the anticholinergic action of some antiarrhythmic drugs.Pharmacol. Res. Commun. 4:171–178 (1972).

    Article  CAS  Google Scholar 

  15. B. Jensen, B. Sigard, and A. Uhrenholt. Hemodynamic effects of intravenous disopyramide in heart failure.Eur. J. Clin. Pharmacol. 8:167–173 (1975).

    Article  CAS  PubMed  Google Scholar 

  16. P. H. Hinderling and E. R. Garrett. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.J. Pharmacokin. Biopharm. 4:199–230 (1976).

    Article  CAS  Google Scholar 

  17. A. M. Weissler, G. L. Morris, and G. D. White. Left ventricular ejection time index in man.J. Appl. Physiol. 18:919–923 (1963).

    CAS  PubMed  Google Scholar 

  18. A. C. Guyton.Textbook of Medical Physiology, 3rd ed., Saunders, Philadelphia, 1968, p. 198.

    Google Scholar 

  19. D. T. Mason, J. F. Spann, R. Zelis, and E. A. Amsterdam. The clinical pharmacology and therapeutic application of the antiarrhythmic drugs.Clin. Pharmacol. Ther. 11:460–480 (1971).

    Google Scholar 

  20. H. C. Bazett. An analysis of the time relationship of the electrocardiogram.Heart 7:353–360 (1920).

    Google Scholar 

  21. M. Kissin, M. M. Schwarzschild, and M. Bakst. A nomogram for rate correction of the Q-T interval in the electrocardiogram.Am. Heart J. 35:990–992 (1948).

    Article  CAS  PubMed  Google Scholar 

  22. A. M. Weissler, R. G. Peeler, and W. M. Roehll. Relationships between left ventricular ejection time, stroke volume and heart rate in normal individuals and patients with cardiovascular disease.Am. Heart J. 62:367–378 (1961).

    Article  CAS  PubMed  Google Scholar 

  23. D. S. Riggs.The Mathematical Approach to Physiological Problems, Williams and Wilkins, Baltimore, 1963, p. 8.

    Google Scholar 

  24. C. Fisch, S. B. Knoebel, M. Feigenbaum, and K. Greenspan. Potassium and the monophasic action potential, electrocardiogram, conduction and arrhythmias.Progr. Cardiovasc. Dis. 8:387–418 (1966).

    Article  CAS  Google Scholar 

  25. E. R. Garrett. In H. P. Kuemmerle, E. R. Garrett, and K. M. Spitzy (eds.),Klinische Pharmakologie und Pharmakotherapie, Urban and Schwarzenberg, Munich, West Germany, 1971, p. 36.

    Google Scholar 

  26. E. R. Garrett, A. J. Ågren, and H. J. Lambert. Pharmacokinetic analysis of receptor site models in multicompartment systems.Int. J. Clin. Pharm. 1:1–14 (1967).

    Google Scholar 

  27. R. R. Dean. In: A seminar on Norpace (disopyramide phosphate), a new antiarrhythmic agent.Angiology 26:98 (1975).

    Google Scholar 

  28. R. Ashman and E. Hull.Essentials of Electrocardiography, 2nd ed., Macmillan, New York, 1941, p. 344.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported in part by Grant No. NIH-RR-82 from the National Institutes of Health, Bethesda, Maryland, and by an unrestricted grant from Searle Laboratories, Skokie, Illinois.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hinderling, P.H., Garrett, E.R. Pharmacodynamics of the antiarrhythmic disopyramide in healthy humans: Correlation of the kinetics of the drug and its effects. Journal of Pharmacokinetics and Biopharmaceutics 4, 231–242 (1976). https://doi.org/10.1007/BF01063615

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01063615

Key words

Navigation